Pfizer Stock News

COVID-19 vaccine sales boosted Pfizer earnings well past analyst expectations in the final quarter of 2021, but the drugmaker is setting a lower-than-expected bar for…

Pfizer (PFE) is trading ~3% lower in the pre-market on Tuesday after the company missed revenue expectations for Q4 2021 on Tuesday despite an earnings beat

Pfizer''s sales in the fourth quarter more than doubled, thanks to strong demand for its Covid-19 vaccine.

(Reuters) – Pfizer Inc on Tuesday raised its forecast for full-year sales of its COVID-19 vaccine to about $32 billion, and said it expects another $22 billion from sales of its oral antiviral pill for the disease.

Shares of Pfizer Inc. sank 2.6% in premarket trading Tuesday, after the drug maker reported fourth-quarter profit that beat expectations, while revenue more than doubled but missed forecasts. The company also provided a full-year outlook that was below analyst projections, but raised its sales guidance for its COVID-19 vaccine Comirnaty developed with BioNTech SE . Net income jumped to $3.39 billion, or 59 cents a share, from $847 million, or 15 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $1.08 from 43 cents, above the FactSet consensus of 87 cents. Revenue grew 104.9% to $23.84 billion, but missed the FactSet consensus of $24.16 billion, with Comirnaty contributing $12.5 billion in sales to beat expectations of $12.38 billion. For 2022, the company raised its sales outlook for Comirnaty to $32 billion from $31 billion, and expects $22 billion of revenue for its oral COVID-19 treatment Paxlovid. Overall, the company expect adjusted EPS of $6.35 to $6.55, below the current FactSet consensus of $6.71, and expects revenue of $98.0 billion to $102.0 billion, below expectations of $103.2 billion.

Pfizer Inc on Tuesday raised its forecast for full-year sales of its COVID-19 vaccine to about $32 billion, and said it expects another $22 billion from sales of its oral antiviral pill for the disease.

Pfizer posted better-than-expected fourth quarter earnings Tuesday, and forecast $54 billion in vaccine and treatment sales for the coming year, as it continues to outpace rivals in Covid treatment developments.

Pfizer projects it will generate record-high revenue in 2022, saying Tuesday it expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid this year.

Companies Reporting Before The Bell Pfizer (NYSE: PFE ) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. Karyopharm Therapeutics (NASDAQ: KPTI ) is likely to report quarterly loss at $0.49 per share on revenue of $50.49 million. Thomson Reuters (NYSE: TRI ) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.68 billion. Beasley Broadcast Group (NASDAQ: BBGI ) is likely to report quarterly earnings at $0.03 per share on revenue of $69.67 million. Willis Towers Watson (NASDAQ: WTW ) is projected to report quarterly earnings at $4.98 per share on revenue of $2.50 billion. Cenovus Energy (NYSE: CVE ) is expected to report quarterly earnings at $0.39 per share on revenue of $11.25 billion. Jacobs Engineering Group (NYSE: J ) is projected to report quarterly earnings at $1.58 per share on revenue of $3.51 billion. CTS (NYSE: CTS ) is estimated to report quarterly earnings at $0.47 per share on revenue of $122.96 million.

A federal judge has rejected a bid by the U.S. Food and Drug Administration and Pfizer to delay the court-ordered release of nearly 400,000 pages of documents pertaining to the approval of Pfizers COVID vaccine. Federal judge Mark Pittman of the U.S. District Court for the Northern District of Texas, in an order issued Feb. The post Court rejects Pfizer, FDA bid to hide COVID vaccine safety data appeared first on National Daily Newspaper .

The mRNA COVID-19 vaccines from Pfizer and Moderna have proved remarkably effective at providing protection from the coronavirus.

https://www.investing.com/news/stock-market-news/pfizer-and-peloton-earnings-api-report--3-things-to-watch-2758784

CDC Signals Changes To COVID Vaccine Schedule, In Part To Address Heart Inflammation Authored by Zachary Stieber via The Epoch Times, The Centers for Disease Control and Prevention (CDC) on Feb. 4 outlined an expected change to the COVID-19 vaccine schedule for people with weak immune systems and signaled that a different alteration is coming for the general population to try to cut the number of post-vaccination heart inflammation cases . The CDC told its vaccine advisory panel that its planning to adjust guidance for people with compromised immune systems, a group that doesnt respond as well to vaccines as the general population and is the only population that is advised to get four doses of the Moderna or Pfizer messenger RNA (mRNA) vaccines. Current CDC guidance for the immunocompromised says they should receive three doses of an mRNA vaccine within two months, and a fourth dose at least five months after the third dose. The revised schedule would recommend the population get that fourth shot as soon as three months after their third one.

Related Stocks: PFE , NTRA , UNP , S , S , LSCC , NFLX , SPSC , ZWS , POWI , LAND , HLIO , EVBG , RETA , CDLX , RPAY , ALLK ,

By Manas Mishra (Reuters) – Investors on Tuesday hope to learn Pfizer Inc’s plans for what could be a once-in-a-generation cash infusion from COVID-19 treatments and vaccines in 2022, with some looking for the drugmaker to spend on deals.